...
首页> 外文期刊>Laboratory investigation >Alterations on the 5|[prime]| Noncoding Region of the BCL-6 Gene Are Not Correlated with BCL-6 Protein Expression in T Cell Non-Hodgkin Lymphomas
【24h】

Alterations on the 5|[prime]| Noncoding Region of the BCL-6 Gene Are Not Correlated with BCL-6 Protein Expression in T Cell Non-Hodgkin Lymphomas

机译:5 | [prime] |的变化BCL-6基因的非编码区与T细胞非霍奇金淋巴瘤中BCL-6蛋白的表达无关

获取原文

摘要

The BCL-6 proto-oncogene is expressed in germinal center B lymphocytes, in their neoplastic counterparts, and in a subpopulation of germinal center and perifollicular T lymphocytes. Rearrangements and/or mutations of the 5' noncoding region of the bcl-6 gene have been demonstrated in a large majority of diffuse large B cell lymphomas. Some, but not all, of these genetic alterations lead to dysregulation of the protein. Recently, anaplastic large cell lymphomas with T and null cell phenotypes, as well as T lymphoblastic lymphomas, have also been reported to exhibit immunoreactivity to the anti-BCL-6 antibody. We collected 33 T cell non-Hodgkin lymphomas (T-NHLs) and analyzed their expression of the BCL-6 protein by immunohistochemistry and investigated the organization of the bcl-6 gene by Southern blot and single strand conformation polymorphism (SSCP). The expression of BCL-6 was demonstrated in 37.5% of lymphoblastic (LBL), 40% of anaplastic large cell (ALCL), and 33% of peripheral T cell lymphomas (PTCL). BCL-6–positive malignant cells exhibited the CD4+ or CD4+/CD8+ phenotype. The bcl-6 gene was in a germline configuration in all T-NHLs examined, and a mutation at the first exon-intron boundary region structure of the wild-type bcl-6 gene was detected in 3 of 12 PTCL. One case of PTCL with mutations of the 5' noncoding region expressed BCL-6. In conclusion, expression of the BCL-6 protein is demonstrable independently of bcl-6 alterations in T-NHLs. This further suggests that molecular mechanisms other than rearrangements and/or mutations of the 5' noncoding region of the bcl-6 gene can result in expression of the protein. Whether these lymphomas arose from T cells expressing BCL-6 or expressed BCL-6 as part of the malignant transformation process needs to be determined. Finally, structural alterations of bcl-6 are rare in T-NHLs, but mutations do occur in the 5' noncoding region. We suggest that expression of BCL-6 in T cells may facilitate lymphomagenesis by repressing critical cytokines and cell cycle regulators.
机译:BCL-6原癌基因在生发中心B淋巴细胞,其肿瘤对应物中以及生发中心和滤泡T淋巴细胞亚群中表达。 bcl-6基因的5'非编码区的重排和/或突变已在绝大多数弥漫性大B细胞淋巴瘤中得到证实。这些遗传改变中的一些(但不是全部)会导致蛋白质失调。最近,也已经报道了具有T和空细胞表型的间变性大细胞淋巴瘤以及T淋巴母细胞淋巴瘤对抗BCL-6抗体表现出免疫反应性。我们收集了33例T细胞非霍奇金淋巴瘤(T-NHLs),并通过免疫组织化学分析了它们在BCL-6蛋白中的表达,并通过Southern印迹和单链构象多态性(SSCP)研究了bcl-6基因的组织。在37.5%的淋巴母细胞(LBL),40%的间变性大细胞(ALCL)和33%的外周T细胞淋巴瘤(PTCL)中证实了BCL-6的表达。 BCL-6阳性恶性细胞表现出CD4 +或CD4 + / CD8 +表型。在所有检查的T-NHL中,bcl-6基因处于种系构型,并且在12个PTCL中的3个中检测到了野生型bcl-6基因的第一个外显子-内含子边界区域结构的突变。一例5L非编码区突变的PTCL表达BCL-6。总之,可以证明BCL-6蛋白的表达与T-NHL中bcl-6的变化无关。这进一步表明,除了bcl-6基因的5'非编码区的重排和/或突变以外的分子机制还可以导致蛋白质的表达。这些淋巴瘤是由表达BCL-6的T细胞还是作为恶性转化过程的一部分表达的BCL-6引起的。最后,bcl-6的结构改变在T-NHL中很少见,但突变确实发生在5'非编码区。我们建议,TCL中BCL-6的表达可能通过抑制关键细胞因子和细胞周期调节剂来促进淋巴瘤的发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号